311 related articles for article (PubMed ID: 24756784)
21. Practical management of dasatinib for maximum patient benefit.
Galinsky I; Buchanan S
Clin J Oncol Nurs; 2009 Jun; 13(3):329-35. PubMed ID: 19502192
[TBL] [Abstract][Full Text] [Related]
22. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib.
Shah NP
Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
[TBL] [Abstract][Full Text] [Related]
24. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
25. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Keating GM; Lyseng-Williamson KA; McCormack PL; Keam SJ
BioDrugs; 2013 Jun; 27(3):275-9. PubMed ID: 23549840
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Apperley JF; Cortes JE; Kim DW; Roy L; Roboz GJ; Rosti G; Bullorsky EO; Abruzzese E; Hochhaus A; Heim D; de Souza CA; Larson RA; Lipton JH; Khoury HJ; Kim HJ; Sillaber C; Hughes TP; Erben P; Van Tornout J; Stone RM
J Clin Oncol; 2009 Jul; 27(21):3472-9. PubMed ID: 19487385
[TBL] [Abstract][Full Text] [Related]
29. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
30. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
[TBL] [Abstract][Full Text] [Related]
31. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Quintás-Cardama A; Kantarjian H; Cortes J
Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
33. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong SF
J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib: a new step in molecular target therapy.
Olivieri A; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi42-6. PubMed ID: 17591830
[TBL] [Abstract][Full Text] [Related]
37. New dosing schedules of dasatinib for CML and adverse event management.
Wong SF
J Hematol Oncol; 2009 Feb; 2():10. PubMed ID: 19236716
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Santos FP; Cortes J
Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib for the treatment of chronic myeloid leukemia.
Fullmer A; Kantarjian H; Cortes J; Jabbour E
Expert Rev Hematol; 2011 Jun; 4(3):253-60. PubMed ID: 21668392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]